SG Americas Securities
IBIO icon

SG Americas Securities’s iBio IBIO Stock Holding History

SG Americas Securities’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56
Closed -$12K – 3494
2022
Q1 		$12K Sell
56
-56
-50% -$11.7K ﹤0.01% 2898
2021
Q4 		$31K Sell
112
-159
-59% -$60.6K ﹤0.01% 3234
2021
Q3 		$144K Buy
+271
New +$169K ﹤0.01% 3459
2021
Q2 		– Sell
-97
Closed -$75K – 3025
2021
Q1 		$75K Buy
97
+71
+273% +$61.9K ﹤0.01% 3119
2020
Q4 		$14K Buy
+26
New +$21.2K ﹤0.01% 3219
2020
Q3 		– Sell
-52
Closed -$58K – 3044
2020
Q2 		$58K Buy
+52
New +$34K ﹤0.01% 3508

Other funds holding IBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SG Americas Securities's IBIO Position: Q2 2022 in Review

SG Americas Securities sold out of iBio (IBIO) in Q2 2022, closing a stake of 56 shares — an estimated $12K sold.

SG Americas Securities first reported a position in IBIO in Q2 2020 and held it in 6 quarters. The position peaked at $144K in Q3 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

  • SG Americas Securities reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
  • SG Americas Securities sold 56 iBio shares in Q2 2022, an estimated $12K.
  • SG Americas Securities first reported a position in iBio in Q2 2020 and held it in 6 quarters.
  • SG Americas Securities's iBio position peaked at $144K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on SG Americas Securities's 13F filing for Q2 2022, filed 29 Jul 2022.